Misplaced Pages

Cefpodoxime: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 12:50, 15 February 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacology|errors← Previous edit Revision as of 01:50, 25 March 2011 edit undoCryocone (talk | contribs)15 edits Removed personal 'side effects' anecdote.Next edit →
Line 62: Line 62:
] ]
] ]
'''Side effects:''' After 3 dose, I suffered from blocked nose or worse, in cold weather, blocked or frozen sputum in chest leading to difficulty in breathing. Confirm with your doctor about possible side effects or allergies

Revision as of 01:50, 25 March 2011

Pharmaceutical compound
Cefpodoxime
Clinical data
Pregnancy
category
  • AU: B1
Routes of
administration		Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability50%
Protein binding21% to 29%
MetabolismNegligible. Cefpodoxime proxetil is metabolized to cefpodoxime by the liver
Elimination half-life2 hours
ExcretionRenal, unchanged
Identifiers
IUPAC name
  • (6R,7R)-7-{amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclooct-2-ene-2-carboxylic acid
CAS Number
PubChem CID
ChemSpider
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.210.871 Edit this at Wikidata
Chemical and physical data
FormulaC15H17N5O6S2
Molar mass427.458 g/mol g·mol
3D model (JSmol)
SMILES
  • O=C2N1/C(=C(\CS12NC(=O)C(=N\OC)/c3nc(sc3)N)COC)C(=O)O
InChI
  • InChI=1S/C15H17N5O6S2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24)/b19-8-/t9-,13-/m1/s1
  • Key:WYUSVOMTXWRGEK-HBWVYFAYSA-N
  (verify)

Cefpodoxime is an oral third generation cephalosporin antibiotic. It is marketed as the prodrug cefpodoxime proxetil by Pharmacia & Upjohn under the trade name Vantin and under the name Orelox by ; PECEF in Dr Reddy's (Farhaad)]. It is active against most Gram positive and Gram negative organisms. Notable exceptions include Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. It also finds use as oral continuation therapy when intravenous cephalosporins (such as ceftriaxone) are no longer necessary for continued treatment.

Pfizer, the parent company of Pharmacia & Upjohn, markets cefpodoxime proxetil under the trade name Simplicef for veterinary use. The dose range in dogs is 5–10 mg/kg body weight, administered orally, once a day.

Structural formula of cefpodoxime proxetil

External links

Antibacterials active on the cell wall and envelope (J01C-J01D)
β-lactams
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)
Penicillins (Penams)
Narrow
spectrum
β-lactamase sensitive
(1st generation)
β-lactamase resistant
(2nd generation)
Extended
spectrum
Aminopenicillins (3rd generation)
Carboxypenicillins (4th generation)
Ureidopenicillins (4th generation)
Other
Carbapenems / Penems
Cephems
Cephalosporins
Cephamycins
Carbacephems
1st generation
2nd generation
3rd generation
4th generation
5th generation
Siderophore
Veterinary
Monobactams
β-lactamase inhibitors
Combinations
Polypeptides
Lipopeptides
Other
  • Inhibits PG elongation and crosslinking: Ramoplanin
Intracellular
Other
Stub icon

This systemic antibiotic-related article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Cefpodoxime: Difference between revisions Add topic